Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KVD900 dose-ranging crossover study for acute hereditary angioedema attacks
ISRCTN14762022Phase 3Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Feb 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sebetralstat in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2) (3 arms), sponsored by KalVista Pharmaceuticals. Primary endpoint: Primary: Time to beginning of symptom relief. Started Feb 2022; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on ISRCTN14762022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14762022.